Holen Sie sich die Stockscreener-App
1.38
2.13%
-0.03
Handel nachbörslich:
1.40
0.02
+1.45%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.41
Offen:
$1.42
24-Stunden-Volumen:
2.04M
Relative Volume:
0.77
Marktkapitalisierung:
$501.49M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.725
EPS:
-0.8
Netto-Cashflow:
$-162.37M
1W Leistung:
+2.99%
1M Leistung:
+23.21%
6M Leistung:
+174.30%
1J Leistung:
-14.29%
1-Tages-Spanne:
$1.355
$1.45
1-Wochen-Bereich:
$1.28
$1.45
52-Wochen-Spanne:
$0.2836
$2.175
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Vergleichen Sie LXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.38 | 512.39M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.85 | 103.64B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.00 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.99 | 60.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
791.59 | 46.96B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
345.17 | 36.81B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-03-07 | Eingeleitet | Jefferies | Hold |
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold |
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Bestätigt | Stifel | Buy |
| 2018-02-23 | Herabstufung | Needham | Buy → Hold |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-01 | Bestätigt | Wedbush | Outperform |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-05 | Bestätigt | Wedbush | Outperform |
| 2016-08-02 | Eingeleitet | Citigroup | Buy |
| 2016-03-02 | Bestätigt | Wedbush | Outperform |
| 2015-11-09 | Bestätigt | Wedbush | Outperform |
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Lexicon Pharmaceuticals Inc Stock Analysis and ForecastRetail Trading Trends & Affordable Trading Portfolio - earlytimes.in
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28% - simplywall.st
Is Lexicon Pharmaceuticals Inc. stock bottoming outJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - newser.com
Detecting price anomalies in Lexicon Pharmaceuticals Inc. with AIJuly 2025 Fed Impact & Daily Growth Stock Tips - newser.com
What’s the recovery path for long term holders of Lexicon Pharmaceuticals Inc.Weekly Trend Report & AI Driven Stock Price Forecasts - newser.com
Lexicon Pharmaceuticals, Inc. $LXRX Stake Reduced by Goldman Sachs Group Inc. - MarketBeat
Can you recover from losses in Lexicon Pharmaceuticals Inc.2025 Price Targets & Low Risk Growth Stock Ideas - newser.com
Is Lexicon Pharmaceuticals Inc. a candidate for recovery playAnalyst Downgrade & Long Hold Capital Preservation Tips - newser.com
Smart tools for monitoring Lexicon Pharmaceuticals Inc.’s price action2025 EndofYear Setup & Free Fast Gain Swing Trade Alerts - newser.com
What analysts say about Lexicon Pharmaceuticals Inc stockContrarian Investment Ideas & Big Gains Low Budget - earlytimes.in
Lexicon reports FDA's decision to extend review period for Zynquista - MSN
Lexicon Pharmaceuticals, Inc. $LXRX Shares Purchased by Compagnie Lombard Odier SCmA - MarketBeat
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes - MarketScreener
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Lexicon awaits FDA feedback on diabetes drug application in Q4 By Investing.com - Investing.com Australia
Lexicon awaits FDA feedback on diabetes drug application in Q4 - Investing.com
Lexicon Pharmaceuticals (LXRX) Faces FDA Review Extension for Zy - GuruFocus
Lexicon pharmaceuticals announces update on submission of additional data to U.S. FDA - MarketScreener
Lexicon expects delay in FDA feedback on additional data for its diabetes drug - Reuters
Lexicon (LXRX) Seeks FDA Feedback on Zynquista with New Data Sub - GuruFocus
Lexicon Pharmaceuticals Provides Update on Zynquista NDA Resubmission Following FDA Feedback - Quiver Quantitative
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes - The Manila Times
FDA Extends Review of Breakthrough Diabetes Drug Zynquista: What Lexicon's New Data Shows - Stock Titan
Nasdaq Moves: Whats the MACD signal for Lexicon Pharmaceuticals IncStop Loss & Verified High Yield Trade Plans - خودرو بانک
Lexicon Pharmaceuticals (NASDAQ:LXRX) Share Price Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
Market Review: What is the target price for Lexicon Pharmaceuticals Inc stockM&A Rumor & Entry Point Strategy Guides - خودرو بانک
Guidance Update: Can Lexicon Pharmaceuticals Inc. reach all time highs this yearMarket Performance Summary & Daily Technical Forecast Reports - خودرو بانک
Geopolitics Watch: Is Lexicon Pharmaceuticals Inc a defensive stockPortfolio Gains Report & Risk Controlled Swing Alerts - خودرو بانک
What makes Lexicon Pharmaceuticals Inc. stock attractive todayWeekly Trend Recap & Reliable Intraday Trade Alerts - خودرو بانک
CEO Moves: What is Lexicon Pharmaceuticals Incs valuation compared to sectorEntry Point & Reliable Volume Spike Alerts - خودرو بانک
How volatile is Lexicon Pharmaceuticals Inc. stock2025 Market WrapUp & Weekly Return Optimization Alerts - خودرو بانک
Lexicon Pharmaceuticals (LXRX) Highlights Promising Phase 2b Stu - GuruFocus
Lexicon Pharmaceuticals Presents Promising Phase 2b Results for Pilavapadin in Treating Diabetic Peripheral Neuropathic Pain - Quiver Quantitative
2-Point Pain Reduction: Lexicon's Non-Opioid Drug Could Be First New DPNP Treatment in 20 Years - Stock Titan
Lexicon Pharmaceuticals Inc. recovery potential after sell offJuly 2025 Big Picture & Safe Entry Momentum Stock Tips - newser.com
Is Vistagen Therapeutics Inc. forming a bullish divergenceTake Profit & Comprehensive Market Scan Reports - خودرو بانک
Breakouts Watch: Whats the MACD signal for Lexicon Pharmaceuticals IncJuly 2025 Short Interest & Free Risk Controlled Daily Trade Plans - خودرو بانک
Aug Update: What’s the MACD signal for NHPAPEarnings Growth Report & AI Driven Stock Price Forecasts - خودرو بانک
Lexicon Pharmaceuticals jumps amid takeover speculation - MSN
Market Outlook: What’s the RSI of Lexicon Pharmaceuticals Inc. stockRecession Risk & Real-Time Volume Triggers - khodrobank.com
Panic Selling: What is Lexicon Pharmaceuticals Inc.’s TAM (Total Addressable Market)2025 Macro Impact & Weekly Market Pulse Updates - khodrobank.com
Market Review: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteriaIPO Watch & Pattern Based Trade Signal System - خودرو بانک
Wall Street Recap: What is Kaltura Inc. s debt to equity ratioJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - khodrobank.com
Published on: 2025-09-16 15:08:33 - خودرو بانک
Buybacks Report: What drives Lexicon Pharmaceuticals Incs stock pricePortfolio Performance Summary & Safe Capital Growth Trade Ideas - خودرو بانک
Performance Recap: Will Lexicon Pharmaceuticals Inc benefit from sector rotationQuarterly Trade Report & Long-Term Capital Growth Ideas - خودرو بانک
Aug Movers: What is the target price for Lexicon Pharmaceuticals Inc stockTrade Risk Assessment & Technical Pattern Based Buy Signals - خودرو بانک
Institution Moves: Is Lexicon Pharmaceuticals Inc stock trending bullish2025 Momentum Check & Community Shared Stock Ideas - خودرو بانک
MACD Signal: Should I hold or sell Lexicon Pharmaceuticals Inc now2025 Historical Comparison & AI Forecast Swing Trade Picks - خودرو بانک
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings - The Manila Times
Lexicon Pharmaceuticals Presents Promising Data on Pilavapadin for Diabetic Peripheral Neuropathic Pain at Upcoming Medical Meetings - Quiver Quantitative
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):